TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Abnormal Electrocardiogram (ECG) Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: combined operative mortality and morbidity
Endpoint domain: Mortality/survival
Primary endpoint: normal immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: safety issues
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of correct answers to telephonic structured interview
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Severe PVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Corrected visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Comfort Wearing Lenses
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ratio of late adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Respiratory status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Echocardiographic assessment under hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: auditory evoked brainstem response (ABR) characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: salivary cortisone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean systematic blood pressure level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24 hour urinary sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Leg Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of dermatologic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decreased Post Operative Ureteral Stent Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less ER Visits/Hospital Admits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient Phone Calls for Stent Pain/Difficulty
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Experiencing DLT
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Plasma Concentration After Administration Of Samalizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under The Plasma Drug Concentration-time Curve After Administration Of Samalizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychological diagnosis test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: behavior observation ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AUC%_Extrap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Percent Fat Mass at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Mean Number of Steps Per Day at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Waist Circumference (Centimeters) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and toleration of stem cell infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Lower Extremity Function scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke Specific Quality of Life Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Compliance measured as the average number of treatments per week
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Volume of erosions on metacarpophalangeal joints (MCP) 2-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Achievement rate of therapeutic efficacy target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximally tolerated dose of AT-101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Premenstrual Syndrome Scale (PMSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SDNN (msec)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fMRI imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Physical activity changes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Questionnaire feedback
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood concentration of YKL-40
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects regarding UCMSC infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of GLY-230
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of GLY-230
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Treatment Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Treatment Emergent Local Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Treatment Emergent Systemic Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Total morphine consumption in 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Positive Viral Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Form (appearance) of stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Hb A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lumbar active range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 100-mm visual analog scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under Curve (AUC) of Evogliptin and Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) of Evogliptin and Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Survival of participants
Endpoint domain: Mortality/survival
Primary endpoint: 1 year PFS rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy, response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Palmar-plantar Erythrodysesthesia (PPE)
Endpoint domain: Adverse events/effects
Primary endpoint: Death at 48h
Endpoint domain: Mortality/survival
Primary endpoint: Unplanned heart failure hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Objective regression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Global Probing Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Plaque Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin graft take
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of cells killed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral Oxygen Tissue Tension (PbrO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regional Cerebral Oximetry (RSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Genetic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Bothersome Visual Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Difficulty With an Activity Due to the Visual Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lung consolidation resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lung nodule diagnosis accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loss of response (LOR) rate at one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization for gastroenteritis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 3-year disease-free survival (3y-DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Biodistribution of OTSA101-DTPA-111In
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of blood spill
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of bruise area
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of blood clot
Endpoint domain: Adverse events/effects
Primary endpoint: patient pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With 50% Reduction of Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence and severity of device/procedure-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportions of treated subjects reporting negative Gleason 7 biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Visual Acuity (VA) logMAR (Habitual Lenses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Acuity (VA) logMAR (Study Lenses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Ease of Lens Handling (Day 1 Study Lenses)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Educators' Observed Implementation Fidelity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Serum IgG Trough Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Electrical signal mean amplitude during AV synchronous pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immunogenicity evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC) of LY3526318
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Drug Concentration (Cmax) of LY3526318
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Reported Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Reported Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in plaque morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Systolic and Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardio-respiratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Endoscopic Response Between Week 16 and 17
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission of diabetes mellitus type II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Radiographic examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary 6-sulphatoxymelatonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in spherical equivalent refractive error (SER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in axial length (AL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of pneumococci in nasopharyngeal swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of fat muscle and oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality after free falls
Endpoint domain: Mortality/survival
Primary endpoint: Visual Acuity (logMAR) at 3 Minutes Post Instillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Acuity (logMAR) at 10 Minutes Post Instillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioelectrical Impedance at 5 kHz for one body side
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioelectrical Impedance at 50 kHz for all 4 extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Myocardial Glucose Utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Myocardial Efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Peak Oxygen Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of Laryngospasm
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Cough
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Clinical Severity Ratings (CSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Opioid Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting at Least One Treatment-Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Treatment Emergent Adverse Events Reported During The Study
Endpoint domain: Adverse events/effects
Primary endpoint: Primary cardiovascular diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nutrient Absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of mannitol-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: clinically significant abnormalities in laboratory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal daily dose of mannitol that does not cause discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvascular obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of blood cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in pain perceptions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anesthesiologist Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptance of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Uptake of [18F]NOS in the human brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasmatic HIV-1 Viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in body fat mass at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in lean body mass at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in body mass index at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's death
Endpoint domain: Mortality/survival
Primary endpoint: Functional cumulative patency rate at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of cumulative drug excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC0-t, AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in liver function indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in degree of steatosis and fibrosis (fibroelastometry method)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in degree of steatosis and fibrosis (ultrasound method)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of esophageal motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of cardiovascular death, ischemic stroke and systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Primary Wound With Complete Wound Healing (100% Wound Closure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device failure or device removal/revision
Endpoint domain: Adverse events/effects
Primary endpoint: Radiographically confirmed loosening and migration
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Systolic Blood Pressure and Diastolic Blood Pressure at Indicated Time Points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Concentration of carotenoids in plasma triacyl-rich-lipoprotein (TRL) fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STI prevalence Endline 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: STI prevalence Endline 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in body composition - Body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in glucose and HbA1c levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number and percentage of subjects with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: laboratory changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number and percentage of subjects with laboratory values that are outside the pre-determined ranges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Rosenberg Self-Esteem (SES)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Symptom CheckList 90-R (SCL90-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to EDSS 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Changes in functional limitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the disability measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in impairments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ridge Dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Rapid Assessment of Physical Activity (RAPA)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients with oligometastatic presentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of lung cancer
Endpoint domain: Mortality/survival
Primary endpoint: Modified lung ultrasound score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: long-term stability of sheath plication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: concentration of vitamin D3 in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concentration of inflammatory markers in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concentration of CRP in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes